Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.46 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3085533 | 0.84 | MMP13 (0.55) | MAPTHDAC6HDAC3HDAC1HDAC4 | |
| SCHEMBL29778896 | 0.81 | ROCK2 (0.62) | MAPTROCK2ROCK1 | |
| SCHEMBL24617406 | 0.81 | ROCK2 (0.62) | MAPTROCK2ROCK1 | |
| SCHEMBL17710874 | 0.76 | EGLN1 (0.46) | KMT2AEGLN1DDR1GAA | |
| SCHEMBL30283377 | 0.75 | EGLN1 (0.45) | MAPTKMT2AEGLN1HDAC6HDAC3 | |
| SCHEMBL17710852 | 0.75 | HSP90AA1 (0.49) | KMT2AEGLN1DDR1ROCK2ROCK1 | |
| SCHEMBL29147374 | 0.74 | MMP13 (0.64) | MAPTDDR1HDAC6HDAC3HDAC1 | |
| SCHEMBL5259359 | 0.73 | APLNR (0.48) | MAPTKMT2AEGLN1HDAC6HDAC3 | |
| SCHEMBL6921490 | 0.73 | LMNA (0.54) | MAPTKMT2AHDAC6GAA | |
| SCHEMBL19669035 | 0.73 | EGLN1 (0.44) | KMT2AEGLN1DDR1GAAROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| EP-1814552-A2 | COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS | Astex Therapeutics Limited (GB) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006051290-A2 | COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | CNKSR1, PRKCH, PRKAR2B | MAPT 1204/4885KMT2A 1763/4885EGLN1 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.